Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41

English version České info

The human monoclonal antibody (mAb) HK20 neutralizes a broad spectrum of primary HIV-1 isolates by targeting the highly conserved heptad repeat 1 (HR1) of gp41, which is transiently exposed during HIV-1 entry. Here we present the crystal structure of the HK20 Fab in complex with a gp41 mimetic 5-Helix at 2.3 Å resolution. HK20 employs its heavy chain CDR H2 and H3 loops to bind into a conserved hydrophobic HR1 pocket that is occupied by HR2 residues in the gp41 post fusion conformation. Compared to the previously described HR1-specific mAb D5, HK20 approaches its epitope with a different angle which might favor epitope access and thus contribute to its higher neutralization breadth and potency. Comparison of the neutralization activities of HK20 IgG, Fab and scFv employing both single cycle and multiple cycle neutralization assays revealed much higher potencies for the smaller Fab and scFv over IgG, implying that the target site is difficult to access for complete antibodies. Nevertheless, two thirds of sera from HIV-1 infected individuals contain significant titers of HK20-inhibiting antibodies. The breadth of neutralization of primary isolates across all clades, the higher potencies for C-clade viruses and the targeting of a distinct site as compared to the fusion inhibitor T-20 demonstrate the potential of HK20 scFv as a therapeutic tool.

Vyšlo v časopise: Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41. PLoS Pathog 6(11): e32767. doi:10.1371/journal.ppat.1001195
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001195

Souhrn

Zdroje

1. WalkerLM

BurtonDR

2010 Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Current Opinion in Immunology 22 3 358 66

2. BuonaguroL

TorneselloML

BuonaguroFM

2007 Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81 10209 10219

3. Karlsson HedestamGB

FouchierRAM

PhogatS

BurtonDR

SodroskiJ

2008 The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 6 143 155

4. WalkerLM

BurtonDR

2010 Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22 358 366

5. DalgleishAG

BeverleyPC

ClaphamPR

CrawfordDH

GreavesMF

1984 The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 763 767

6. KlatzmannD

ChampagneE

ChamaretS

GruestJ

GuetardD

1984 T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 767 768

7. HuangCC

TangM

ZhangMY

MajeedS

MontabanaE

2005 Structure of a V3-containing HIV-1 gp120 core. Science 310 1025 1028

8. MooreJP

TrkolaA

DragicT

1997 Co-receptors for HIV-1 entry. Curr Opin Immunol 9 551 562

9. BergerEA

MurphyPM

FarberJM

1999 Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17 657 700

10. WeissenhornW

HinzA

GaudinY

2007 Virus membrane fusion. FEBS Lett 581 2150 2155

11. HarrisonSC

2008 Viral membrane fusion. Nat Struct Mol Biol 15 690 698

12. Munoz-BarrosoI

DurellS

SakaguchiK

AppellaE

BlumenthalR

1998 Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 140 315 323

13. FurutaRA

WildCT

WengY

WeissCD

1998 Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5 276 279

14. MatthewsT

SalgoM

GreenbergM

ChungJ

DeMasiR

2004 Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3 215 225

15. WeissenhornW

DessenA

HarrisonSC

SkehelJJ

WileyDC

1997 Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 426 430

16. ChanDC

FassD

BergerJM

KimPS

1997 Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 263 273

17. CaffreyM

CaiM

KaufmanJ

StahlSJ

WingfieldPT

1998 Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J 17 4572 4584

18. BuzonV

NatrajanG

SchibliD

CampeloF

KozlovMM

2010 Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions. PLoS Pathog 6 e1000880

19. MelikyanGB

MarkosyanRM

HemmatiH

DelmedicoMK

LambertDM

2000 Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151 413 423

20. de RosnyE

VassellR

JiangS

KunertR

WeissCD

2004 Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 78 2627 2631

21. DimitrovAS

JacobsA

FinneganCM

StieglerG

KatingerH

2007 Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion. Biochemistry 46 1398 1401

22. FreyG

PengH

Rits-VollochS

MorelliM

ChengY

2008 A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105 3739 3744

23. MillerMD

GeleziunasR

BianchiE

LennardS

HrinR

2005 A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102 14759 14764

24. NelsonJD

KinkeadH

BrunelFM

LeamanD

JensenR

2008 Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology 377 170 183

25. LouisJM

NesheiwatI

ChangL

CloreGM

BewleyCA

2003 Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 278 20278 20285

26. LouisJM

BewleyCA

GustchinaE

AnianaA

CloreGM

2005 Characterization and HIV-1 fusion inhibitory properties of monoclonal Fabs obtained from a human non-immune phage library selected against diverse epitopes of the ectodomain of HIV-1 gp41. J Mol Biol 353 945 951

27. GustchinaE

LouisJM

LamSN

BewleyCA

CloreGM

2007 A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 81 12946 12953

28. GustchinaE

LouisJM

FrischC

YleraF

LechnerA

2009 Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naive human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth. Virology 393 112 119

29. BianchiE

JoyceJG

MillerMD

FinnefrockAC

LiangX

2010 Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 107 23 10655 60

30. RootMJ

KayMS

KimPS

2001 Protein design of an HIV-1 entry inhibitor. Science 291 884 888

31. LuftigMA

MattuM

Di GiovineP

GeleziunasR

HrinR

2006 Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol 13 740 747

32. EckertDM

MalashkevichVN

HongLH

CarrPA

KimPS

1999 Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 103 115

33. SiaSK

CarrPA

CochranAG

MalashkevichVN

KimPS

2002 Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A 99 14664 14669

34. CortiD

LangedijkJPM

HinzA

SeamanMS

VanzettaF

2010 Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE 5 1 e8805

35. SchibliDJ

WeissenhornW

2006 Class I and class II viral fusion protein structures reveal similar principles in membrane fusion. Mol Membr Biol 21 361 371

36. HamburgerAE

KimS

WelchBD

KayMS

2005 Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280 12567 12572

37. StoddartCA

NaultG

GalkinaSA

ThibaudeauK

BakisP

2008 Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283 34045 34052

38. SuhreK

SanejouandY-H

2004 ElNemo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement. Nucl Acids Res 32 W610 614

39. MontgomeryDL

WangYJ

HrinR

LuftigM

SuB

2009 Affinity maturation and characterization of a human monoclonal anti2body against HIV-1 gp41. MAbs 1 462 474

40. GagnonP

HenselF

RichiersiR

2008 Purification of IgM monoclonal antibodies. BioPharm International Supplements Mar 2 2008

41. WildC

OasT

McDanalC

BolognesiD

MatthewsT

1992 A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 89 10537 10541

42. FerrerM

KapoorTM

StrassmaierT

WeissenhornW

SkehelJJ

1999 Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 6 953 960

43. VincentN

KoneA

ChanutB

LuchtF

GeninC

2008 Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates. Aids 22 2075 2085

44. FenyoEM

HeathA

DispinseriS

HolmesH

LussoP

2009 International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 4 e4505

45. ChoudhryV

ZhangMY

HarrisI

SidorovIA

VuB

DimitrovAS

2006 Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun 348 1107 1115

46. MiyauchiK

KimY

LatinovicO

MorozovV

MelikyanGB

2009 HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137 433 444

47. RimskyLT

ShugarsDC

MatthewsTJ

1998 Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72 986 993

48. LuJ

DeeksSG

HohR

BeattyG

KuritzkesBA

2006 Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr 43 60 64

49. KilbyJM

HopkinsS

VenettaTM

DiMassimoB

CloudGA

1998 Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4 1302 1307

50. NaiderF

AnglisterJ

2009 Peptides in the treatment of AIDS. Curr Opin Struct Biol 19 473 482

51. HrinR

MontgomeryDL

WangF

CondraJH

AnZ

2008 Short communication: In vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV Type 1 gp41. AIDS Res Hum Retroviruses 24 1537 1544

52. StewartKD

SteffyK

HarrisK

HarlanJE

StollVS

2007 Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery. J Comput Aided Mol Des 21 121 130

53. EckertDM

MalashkevichVN

KimPS

1998 Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 284 859 865

54. LeslieAGW

1992 Recent changes to the MOSFLM package for processing film and image plate data. Jnt CCP4/ESF-EACMB Newslett Protein Crystallogr 26

55. EvansP

2006 Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62 72 82

56. CCP4 1994 The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50 157 163

57. McCoyAJ

Grosse-KunstleveRW

AdamsPD

WinnMD

StoroniLC

2007 Phaser crystallographic software. J Appl Crystallogr 40 658 674

58. PerrakisA

MorrisR

LamzinVS

1999 Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6 458 463

59. EmsleyP

CowtanK

2004 Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 2126 2132

60. MurshudovGN

VaginAA

DodsonEJ

1997 Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 240 255 |

61. LiM

GaoF

MascolaJR

StamatatosL

PolonisVR

2005 Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 10108 10125

62. LiM

Salazar-GonzalezJF

DerdeynCA

MorrisL

WilliamsonC

2006 Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80 11776 11790

63. ScarlattiG

TresoldiE

BjorndalA

FredrikssonR

ColognesiC

1997 In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3 1259 1265

64. GornyMK

WilliamsC

VolskyB

ReveszK

CohenS

2002 Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 76 9035 9045

65. ScarlattiG

AlbertJ

RossiP

HodaraV

BiraghiP

1993 Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 168 207 210